Abstract
Essential hypertension is a common health disorder with uncertain etiology and unclear pathophysiology. There is evidence that various systems interact in uncertain ways and mechanisms to cause hypertension. It is also well known that inflammation is a key feature in the initiation, progression and clinical implication of several cardiovascular diseases. Recently, it has become evident that the immune system and inflammatory response are also essential in the pathogenesis of hypertension.
Many inflammation markers such as CRP, cytokines, and adhesion molecules have been found elevated in hypertensive patients supporting the role of inflammation in the pathogenesis of hypertension. Also, in normotensive individuals, these markers have been associated with the risk of developing hypertension, whereas in hypertensive patients they have been associated with target organ damage as well as with the risk for future cardiovascular events. Thus, understanding the role of inflammation in hypertension provides new insights for novel therapeutic approaches, targeting inflammation for the treatment of hypertension and its complications.
Keywords: Adhesion molecules, biomarkers, CRP, cytokines, hypertension, inflammation, target organ damage, treatment.
Medicinal Chemistry
Title:Inflammation Markers in Essential Hypertension
Volume: 10 Issue: 7
Author(s): Dimitrios Tsounis, Georgios Bouras, Georgios Giannopoulos, Charalampos Papadimitriou, Dimitrios Alexopoulos and Spyridon Deftereos
Affiliation:
Keywords: Adhesion molecules, biomarkers, CRP, cytokines, hypertension, inflammation, target organ damage, treatment.
Abstract: Essential hypertension is a common health disorder with uncertain etiology and unclear pathophysiology. There is evidence that various systems interact in uncertain ways and mechanisms to cause hypertension. It is also well known that inflammation is a key feature in the initiation, progression and clinical implication of several cardiovascular diseases. Recently, it has become evident that the immune system and inflammatory response are also essential in the pathogenesis of hypertension.
Many inflammation markers such as CRP, cytokines, and adhesion molecules have been found elevated in hypertensive patients supporting the role of inflammation in the pathogenesis of hypertension. Also, in normotensive individuals, these markers have been associated with the risk of developing hypertension, whereas in hypertensive patients they have been associated with target organ damage as well as with the risk for future cardiovascular events. Thus, understanding the role of inflammation in hypertension provides new insights for novel therapeutic approaches, targeting inflammation for the treatment of hypertension and its complications.
Export Options
About this article
Cite this article as:
Tsounis Dimitrios, Bouras Georgios, Giannopoulos Georgios, Papadimitriou Charalampos, Alexopoulos Dimitrios and Deftereos Spyridon, Inflammation Markers in Essential Hypertension, Medicinal Chemistry 2014; 10 (7) . https://dx.doi.org/10.2174/1573406410666140318111328
DOI https://dx.doi.org/10.2174/1573406410666140318111328 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Inflammatory Drugs and Statins for Arterial Stiffness Reduction
Current Pharmaceutical Design Use of Contrast Echocardiography in Intensive Care and at the Emergency Room
Current Cardiology Reviews Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Environmental Factors and Hypertension
Current Pharmaceutical Design Renin-Angiotensin Antagonists: Therapeutic Effects Beyond Blood Pressure Control?
Current Pharmaceutical Design To Be-et, or Not to Be-et, That is the Question: The Role(s) of Nitrate and Nitrite in Health and Illness
Reviews on Recent Clinical Trials Role of Adiponectin in the Metabolic Syndrome: Current Perspectives on its Modulation as a Treatment Strategy
Current Pharmaceutical Design Giant Pulmonary Artery Aneurysm Secondary To Patent Ductus Arteriosus: A Case Report
Current Cardiology Reviews Thyrotoxic Periodic Paralysis: A Concise Review of the Literature
Current Rheumatology Reviews Dysglycemia and Abdominal Obesity
Current Vascular Pharmacology Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Treatment of Acute Hypercalcemia
Medicinal Chemistry Nutrition and Physical Activity on Hypertension: Implication of Current Evidence and Guidelines
Current Hypertension Reviews Cytochrome P450 and the Biological Clock in Mammals
Current Drug Metabolism Cardiovascular Effects of Coumarins Besides their Antioxidant Activity
Current Topics in Medicinal Chemistry The Role of Mitochondrial Dysfunction in Heart Failure and Potential Therapeutic Targets
Current Pharmaceutical Design The Repurposing of Old Drugs or Unsuccessful Lead Compounds by in Silico Approaches: New Advances and Perspectives
Current Topics in Medicinal Chemistry The Interplay Between Asthma and Other Diseases: Role of Ca2+/cAMP Signalling
Endocrine, Metabolic & Immune Disorders - Drug Targets Insulin Resistance in the HIV-Infected Population: The Potential Role of Mitochondrial Dysfunction
Current Drug Targets - Infectious Disorders Hypertension in Children with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Current Hypertension Reviews